On Friday, federal lawmakers will decide the fate of the Rohrabacher-Blumenauer Amendment (formerly known as Rohrabacher-Farr), which currently protects state medical cannabis programs from federal government interference. The Rohrabacher-Blumenauer Amendment (“Amendment”), read literally, prohibits the Department of Justice (“DOJ”) from using federal funds to prevent states from implementing medical cannabis laws. DOJ has previously challenged this interpretation, most notably in a case before the Ninth Circuit Court of Appeals, arguing that the Amendment only prohibits DOJ from prosecuting state government officials responsible for implementing medical cannabis programs. Thankfully, the 9th Circuit ultimately rejected DOJ’s interpretation of the amendment, holding that protection extended to medical cannabis patients, growers, and distributors that are in full, unambiguous compliance with state medical cannabis laws and regulations.
First passed in 2014 as part of an omnibus spending bill, the Amendment has been continuously renewed by federal lawmakers via short-term spending legislation and was last renewed in December as part of a stopgap spending measure. Federal lawmakers have demonstrated increasing support for the Amendment since 2014, so if Congress agrees to pass short-term spending legislation, it is very likely the Amendment will be renewed as well. However, if federal lawmakers fail to pass any form of spending legislation by Friday, the Rohrabacher-Blumenauer Amendment will automatically expire.
While it is impossible to predict what will happen between now and Friday, it appears that Congress is poised to pass a short-term spending bill (called a “Continuing Resolution”) to allow more time for federal budget negotiations. Under this scenario, federal lawmakers can renew Rohrabacher-Blumenauer as part of the short-term spending bill, thus extending protection for medical cannabis states for the time being. If a short-term budget bill does not include the Rohrabacher Amendment, then medical cannabis states would lack any form of protection from DOJ interference. However, even if the short-term spending bill does not include the amendment, it is not the end of the road for Rohrabacher, as Congress must eventually pass federal budget legislation, which would allow for inclusion of the provision once again.
In the alternative, Congress could fail to pass any form of spending legislation before Friday, leading to a partial federal government shutdown. While it sounds scary, a partial shutdown would likely be the second-best scenario for the industry, as DOJ would lack the funding necessary to proceed with a crackdown on medical cannabis states. The best case scenario? Congress renews Rohrabacher-Blumenauer by midnight on Friday, either as part of a short-term spending bill, or longer-term federal budget legislation. In light of the recent changes to DOJ’s cannabis enforcement policy (as discussed in this Client Alert Letter), renewal of Rohrabacher-Blumenauer is more important than ever before. If you feel so inclined, please reach out to your Congressional representatives and speak with them about the importance of extending protections for medical cannabis states.
If you would like additional information on this matter, please feel free to reach out to Emily Burns at firstname.lastname@example.org.
It is important to note that this decision is only legally binding in states located within the jurisdiction of the 9th Circuit, although the case is often cited by lower courts located outside of the 9th Circuit.
ABOUT EMILY BURNS
Emily became passionate about pursuing a legal career in the cannabis industry while attending Vanderbilt Law School, as she had the opportunity to enroll in one of the nation’s first Marijuana Law and Policy courses, taught by leading marijuana law and policy scholar, Professor Robert Mikos. Emily soon began assisting Professor Mikos with writing a first-of-its-kind casebook entitled Marijuana Law, Policy, and Authority, acquiring in-depth knowledge of the various state regulations governing cannabis consumers, producers, and other third parties. In addition to having expert knowledge of the complex legal issues presented by conflicting federal-state marijuana laws, Emily is also involved in marijuana policy reform efforts at the federal level. By incorporating her knowledge of marijuana policy with her understanding of the legal and regulatory environment, Emily is able to anticipate and identify potential legal concerns ex-ante.
ABOUT OFFIT KURMAN
Offit Kurman is one of the fastest-growing, full-service law firms in the Mid-Atlantic region. With over 140 attorneys offering a comprehensive range of services in virtually every legal category, the firm is well positioned to meet the needs of dynamic businesses and the people who own and operate them. Our eleven offices serve individual and corporate clients in the Virginia, Washington, DC, Maryland, Delaware, Pennsylvania, New Jersey, and New York City regions. At Offit Kurman, we are our clients’ most trusted legal advisors, professionals who help maximize and protect business value and personal wealth. In every interaction, we consistently maintain our clients’ confidence by remaining focused on furthering their objectives and achieving their goals in an efficient manner. Trust, knowledge, confidence—in a partner, that’s perfect.
You can connect with Offit Kurman via our Blog, Facebook, Twitter, Google+, YouTube, and LinkedIn pages. You can also sign up to receive Law Matters, Offit Kurman’s monthly newsletter covering a diverse selection of legal and corporate thought leadership content.
MARYLAND | PENNSYLVANIA | VIRGINIA| NEW JERSEY | NEW YORK | DELAWARE | WASHINGTON, DC